Brief: Biontech And Medigene Announce Global Collaboration To Advance T Cell Receptor Immunotherapies Against Cancer

Medigene AG

21/02/2022 18:34

Feb 21 (Reuters) - BioNTech SE  22UAy.DE :
    * BIONTECH AND MEDIGENE ANNOUNCE GLOBAL COLLABORATION TO
ADVANCE T
CELL RECEPTOR IMMUNOTHERAPIES AGAINST CANCER
    * BIONTECH SE - BIONTECH TO ACQUIRE PRECLINICAL PRAME TCR
AND
RECEIVE LICENSES TO MEDIGENE'S PD1-41BB SWITCH RECEPTOR AND
PRECISION PAIRING TECHNOLOGIES
    * BIONTECH SE - BIONTECH WILL HOLD EXCLUSIVE WORLDWIDE
DEVELOPMENT
AND COMMERCIALIZATION RIGHTS TO ALL TCR THERAPIES ARISING FROM
COLLABORATION
    * BIONTECH SE - MEDIGENE WILL RECEIVE EUR 26 MILLION UPFRONT
FROM
BIONTECH, AS WELL AS RESEARCH FUNDING
    * BIONTECH - MEDIGENE WILL BE ELIGIBLE TO GET MILESTONE
PAYMENTS
IN ADDITION TO ROYALTIES & TIERED DEFERRED OPTION PAYMENTS ON
GLOBAL NET SALES

Source text for Eikon:  ID:nGNX3VYxVd 
Further company coverage:  22UAy.DE 

 ((Reuters.Briefs@thomsonreuters.com;))